Herbert Loong, MBBS, FASCO
@herbloong
Academic medical oncologist @ Hong Kong w/ interests in sarcoma medical oncology, thoracic oncology & phase 1 trials | Disclosures:
2.9K Following 4.8K Followers
#PingChi# from @MSKCancerCenter presented on the #final# results of FIH #NB003# trial, a potent and selective KIT inhibitor in GISTs. Broad spectrum of activity seen in different mutations. Phase 3 trial compared with #regorafenib# planned.
@ctosociety @Liferaftgroup @myESMO #ESMO26# #ESMOAmbassadors#
Show more
